Fusion with ARRDC1 or CD63: A Strategy to Enhance p53 Loading into Extracellular Vesicles for Tumor Suppression
Biomolecules · 2024
DOI: 10.3390/biom14050591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Min Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China. Hauptthemen laut MEDLINE: Apoptosis, Extracellular Vesicles, Tumor Suppressor Protein p53, Recombinant Fusion Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hunan Provincial Natural Science Foundation of China, the Postgraduate Freedom Exploration Project of Central South University, the Natural Science Foundation of Changsha.
Abstract (Originalsprache)
Small extracellular vesicles (sEVs) have emerged as promising therapeutic agents and drug delivery vehicles. Targeted modification of sEVs and their contents using genetic modification strategies is one of the most popular methods. This study investigated the effects of p53 fusion with arrestin domain-containing protein 1 (ARRDC1) and CD63 on the generation of sEVs, p53 loading efficiency, and therapeutic efficacy. Overexpression of either ARRDC1–p53 (ARP) or CD63–p53 (CDP) significantly elevated p53 mRNA and protein levels. The incorporation of ARRDC1 and CD63 significantly enhanced HEK293T-sEV biogenesis, evidenced by significant increases in sEV-associated proteins TSG101 and LAMP1, resulting in a boost in sEV production. Importantly, fusion with ARRDC1 or CD63 substantially increased the efficiency of loading both p53 fusion proteins and its mRNA into sEVs. sEVs equipped with ARP or CDP significantly enhanced the enrichment of p53 fusion proteins and mRNA in p53-null H1299 cells, resulting in a marked increase in apoptosis and a reduction in cell proliferation, with ARP-sEVs demonstrating greater effectiveness than CDP-sEVs. These findings underscore the enhanced functionality of ARRDC1- and CD63-modified sEVs, emphasizing the potential of genetic modifications in sEV-based therapies for targeted cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
- Department of Cell Biology, School of Life Sciences, Central South University, Changsha 410013, China.
- Hunan Key Laboratory of Basic and Applied Hematology, Central South University, Changsha 410078, China.
- Hunan Key Laboratory of Animal Models for Human Diseases, Central South University, Changsha 410078, China.
ORCID-Profile: Min Liu, Yiti Zhang, Mujun Liu, Xionghao Liu
Förderung
- Hunan Provincial Natural Science Foundation of China
- the Postgraduate Freedom Exploration Project of Central South University
- the Natural Science Foundation of Changsha
Zitieren
APA
Liu, M., Zhang, Y., He, J., Liu, W., Li, Z., Zhang, Y., Gu, A., Zhao, M., Liu, M., & Liu, X. (2024). Fusion with ARRDC1 or CD63: A Strategy to Enhance p53 Loading into Extracellular Vesicles for Tumor Suppression. Biomolecules. https://doi.org/10.3390/biom14050591
Vancouver
Liu M, Zhang Y, He J, Liu W, Li Z, Zhang Y, et al. Fusion with ARRDC1 or CD63: A Strategy to Enhance p53 Loading into Extracellular Vesicles for Tumor Suppression. Biomolecules. 2024. doi:10.3390/biom14050591
BibTeX
@article{Liu2024,
author = {Liu, Min and Zhang, Yu and He, Jianfeng and Liu, Wanxi and Li, Zhexuan and Zhang, Yiti and Gu, Ao and Zhao, Mingri and Liu, Mujun and Liu, Xionghao},
title = {Fusion with ARRDC1 or CD63: A Strategy to Enhance p53 Loading into Extracellular Vesicles for Tumor Suppression},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14050591}
}
EUVIMED